Successful Completion of Phase 1b Clinical Trial for Caplyta LAI Formulation

Johnson & Johnson's subsidiary, Intra-Cellular Therapies, Inc. (ITCI), has completed a Phase 1b clinical trial (NCT06627413) of lumateperone (brand name Caplyta), a long-acting injectable (LAI) formulation for the treatment of schizophrenia and schizoaffective disorder. This study focused on evaluating the safety, tolerability, and pharmacokinetic (PK) profile after a single intramuscular (IM) injection, laying the groundwork for the next-generation formulation. This is a significant milestone, especially considering Johnson & Johnson's acquisition of Intra-Cellular Therapies for USD 14.6 billion in April 2025. The success of this early-stage trial marks a crucial first step in extending the excellent efficacy of the existing oral Caplyta to a long-acting injectable formulation.

Improving Medication Adherence to Prevent Schizophrenia Relapses

A major challenge for healthcare professionals and patients in the treatment of schizophrenia is the recurrence of symptoms due to inconsistent medication adherence and repeated hospitalizations. The existing oral medications require patients to take them daily, which can be difficult for patients with cognitive impairment. The long-acting injectable formulation currently under development aims to address this issue by maintaining stable drug levels in the blood for an extended period with a single injection, significantly reducing the patient's burden. This will help prevent severe exacerbations of symptoms and enable patients to return to their daily lives more stably, offering an innovative treatment option.

Securing Scientific Pharmacokinetic Data to Accelerate Development

The completion of this Phase 1b clinical trial provides detailed pharmacokinetic data for the lumateperone LAI formulation, which will serve as a precise guideline for subsequent development. By accurately analyzing the rate at which the drug is released into the body and its half-life, a scientific basis has been established for designing a patient-specific dosing schedule (interval) in future Phase 2 and Phase 3 trials. Lumateperone is a serotonin 5-HT2A receptor antagonist and a dopamine D2 receptor partial agonist with excellent metabolic safety. The confirmation that these unique pharmacological properties are maintained in the injectable formulation further enhances the prospects for success in the next clinical stages.

Strategy to Capture a Share of the USD 11.5 Billion Global LAI Market

The global long-acting injectable (LAI) market for schizophrenia is projected to grow rapidly to approximately USD 11.5 billion by 2034, representing a promising area. Currently, this market is dominated by competitors such as Invega Sustenna from Janssen and Uzedy from Teva. Johnson & Johnson aims to cultivate the Caplyta LAI formulation as a key defensive product to counter the patent expiration of its existing flagship products. In 2024, Caplyta achieved sales of USD 680.5 million, representing a 47% growth rate. If the injectable formulation is successfully developed, it has the potential to become a leading blockbuster treatment.